Oncology means an area of medical science which deals with tumours and cancers. The word onco means mass, bulk, or tumor while logy means study. A medical practitioner who treats oncology is known as an oncologist. Usually, an oncologist deals with care and treatment once a person is diagnosed with cancer. Cancer is an abnormal cell growth with the possibility to spread or invade to other parts of the body as well. Not all tumors are cancerous which benign tumors do not extend to other body parts. Cancer also called as a malignant neoplasm or malignant tumor.
Conference Series Ltd organizes numerous Cancer conferences on different types of cancers such as breast cancer, leukemia, oral cancer, skin cancer, lung cancer, colon cancer, rectal cancer, prostate cancer, cervical cancer, melanoma and carcinoma. Symptoms may vary depending on the type. Cancer treatment may include chemotherapy, radiation, and/or surgery. Now a day’s vaccines were also available for specific cancer.
Numerous Oncology & Cancer Conferences are organized by Conference Series Ltd. 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business through different parts of the globe such as USA, Canada, Europe, UK, Middle East, UAE and other Asia Pacific region. Young Researcher Forum, Best poster awards, E-poster, Live Streaming, B2B meetings, exhibition and sponsorship opportunities are other significant features of these Cancer Meetings.
Oncology conferences and Cancer meetings provide an excellent opportunity for the budding scientists and young researchers through its special initiatives like Young Researcher Forum, Poster Presentation and E-poster and Live Streaming, B2B and Scientific Meetings. B2B Meetings are a quick and easy way to meet potential cooperation partners.
About 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008 worldwide, with 56% of the cases and 64% of the deaths in the economically developing world. Breast cancer, the most common tumour in women, presents a high survival percentage: 83% of patients have survived this type of cancer after five years. Lung cancer is one of the most aggressive tumors and survival after five years is very low: only 10% of patients diagnosed with a malignant neoplasm survive for more than five years. Colorectal cancer (of the colon and rectum), the most common malignant tumour if we group men and women together, presents an average survival rate of 50-55% five years after diagnosis, meaning that half the patients survive this form of cancer. Prostate cancer, today the most common tumour in men, has an increasingly favourable prognosis, with a global survival rate of 76%, which is higher in young adults. Ovarian cancer presents a very varied prognosis depending on age: whilst 70% of the group between 15 and 44 years survives this form of cancer, this is the case for only 19% of those over 74 years-old.
The global cancer/tumor profiling market was valued at $13.30 billion in 2012. At the end of 2013, the market is estimated to be $14.99 billion and is poised to reach around $35 billion by 2018, growing at a CAGR of 18.50% from 2013 to 2018. Global oncology spending hit $91 billion for 2013 and it's growing at a 5% clip annually, which will cross $100 billion in 2015. The key players in the cancer/tumor profiling market are Boreal Genomics Inc. (U.S.), Caris Life Sciences (U.S.), Genomic Health Inc. (U.S.), Illumina Inc. (U.S.), Life Technologies Corporation (U.S.), NeoGenomics Laboratories (U.S.), Oxford Gene Technology Ltd. (U.K.), Precision Therapeutics Inc. (U.S.), bioTheranostics (U.S.), Proteome Sciences PLC (U.K.), Agendia (The Netherlands), Nanostring Technologies (U.S.), Rational Therapeutics (U.S.), Oncopath Laboratories (U.S.), and RiboMed BiotechnologiesInc. (U.S.). Global cancer diagnostics market is expected to reach $13.1 Billion in 2020 from an estimated $7.1 Billion in 2015, growing at a CAGR of 12.9%. The market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). The cancer diagnostics market in Asia is expected to grow at the highest rate from 2015 to 2020. According to the market the global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020.
Target audiences at Oncology and Cancer conferences
Program Enquiries | Symposia/Workshops | Sponsorships | Media Partners | Advertising @ firstname.lastname@example.org